ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

Anti-PRL-3 Monoclonal Antibody PRL3-zumab

Also written as “PRL3-ZUMAB” and “PRL3-zumab”.

Its studies are mostly in Macular Degeneration · Neoplasms, led by Intra-IMMUSG Pte.

Drug pageAnti-PRL-3 Monoclonal Antibody PRL3-zumab: every studyAll 6 studies of it, academic ones too, with its approvals, label and forms.
Furthest: phase 3, since Nov 24, 20254 company-led studies, 4 open or runningNext primary completion: Dec 2026 (phase 3)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Intra-IMMUSG Pte44 open or runningphase 3since Nov 24, 2025Jun 22, 2020Dec 2026phase 3 · NCT07290088

Also a collaborator on its studies: Parexel.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Jun 22, 2020First study: phase 2 study in NeoplasmsFirst studyNCT04452955 · 51 enrolled · United States
  2. Nov 24, 2025Phase 3 study in Advanced Solid CancersPhase 3 reachedNCT07290088 · 52 planned · Malaysia
  3. Apr 15, 20262 phase 2 studiesNCT07541001, NCT07547228

Ahead

  1. Dec 2026Primary completion: phase 3 study in Advanced Solid CancersNCT07290088
  2. Dec 1, 2026Primary completion: phase 2 study in NeoplasmsNCT04452955
  3. Feb 7, 2027Primary completion: phase 2 study in Neovascular Age Related Macular DegenerationNCT07547228

TargetBeta

PTP4A3 →read by rule
“A humanized monoclonal antibody against phosphatase of regenerating liver 3 (PRL-3; PTP4A3), ”NCIt, by rule

Studies

All 4 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07547228Neovascular Age Related Macular Degeneration · Singapore2RecruitingFeb 7, 202715
NCT07541001Advanced Malignant Solid Tumor · China2Active, not recruitingJun 1, 202660
NCT07290088Advanced Solid Cancers · Malaysia3RecruitingDec 202652
NCT04452955Neoplasms · United States2Active, not recruitingDec 1, 202651

How it is read

Names in the registry

  • “PRL3-ZUMAB”, 3 entries
  • “PRL3-zumab”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.